{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:43:59Z","timestamp":1789699439059,"version":"4.0.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Genetic alterations of <jats:italic toggle=\"yes\">KIT<\/jats:italic> gene are known to be one of the major causes of melanoma. Those are more common in the mucous and acral subtypes and KIT is regarded as major oncogene in Asian melanomas, where the prevalence of these subtypes is high. Up to date, several clinical trials have been conducted to target <jats:italic toggle=\"yes\">KIT<\/jats:italic> gene alterations in melanoma with unsatisfied efficacies. Imatinib mesylate, a small-molecule inhibitor of the KIT tyrosine kinase, provides a rapid but not durable clinical response in <jats:italic toggle=\"yes\">KIT<\/jats:italic>-mutant melanoma. Meanwhile, recent basic and clinical evidence have revealed another aspect of KIT-targeted therapy, namely the enhancement of antitumor activity of immune checkpoint inhibitors. Herein, we designed clinical trial of co-administrating imatinib mesylate and pembrolizumab (anti-PD-1 antibody) to evaluate its safety and efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and analysis:<\/jats:title>\n            <jats:p>This is an open-label, single-arm, phase I\/II clinical trial involving Japanese patients with metastatic <jats:italic toggle=\"yes\">KIT<\/jats:italic>-mutant melanoma that are refractory to standard therapy including anti-PD-1 therapy. Phase I study is a dose-escalation study comprising two dose levels of imatinib mesylate (200 and 400\u200amg\/day, respectively) with fixed dose of pembrolizumab (200\u200amg every 3\u200aweeks) to evaluate safety and tolerability and determine recommended phase II dose. The primary endpoint of the phase II study is the objective response rate after 4 cycles (3\u200aweeks\/cycle) of pembrolizumab and imatinib mesylate at the dose determined in phase I, based on RECIST version 1.1. A Simon's minimax two-stage design is employed to test the null hypothesis of a 5% response rate vs 30% alternative, which will be rejected when a lower confidence limit of two-sided 90% confidence interval of true response rate is over than threshold response rate. The secondary endpoints include progression free survival, overall survival, best overall response and incidence of adverse events. Totally, a target size of 22 patients will be expected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>If this study shows efficacy and acceptable safety profile, it will contribute to the development of novel treatment option for patients with <jats:italic toggle=\"yes\">KIT<\/jats:italic>-mutant melanoma that are refractory to standard therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>NCT04546074. Date of Registration: September 11, 2020 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04546074). Date of First Participant Enrollment: December 23, 2020.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027832","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T13:05:23Z","timestamp":1639141523000},"page":"e27832","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy"],"prefix":"10.1097","volume":"100","author":[{"given":"Ikuko","family":"Hirai","sequence":"first","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Tanese","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Fusumae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Amagai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-4590","authenticated-orcid":false,"given":"Takeru","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-018-0414-1","article-title":"KIT as an oncogenic driver in melanoma: an update on clinical development","volume":"20","author":"Meng","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":"Large-scale analysis of KIT aberrations in Chinese patients with melanoma","volume":"17","author":"Kong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","article-title":"Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients","volume":"80","author":"Sakaizawa","year":"2015","journal-title":"J Dermatol Sci"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1634\/theoncologist.2015-0161","article-title":"Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: a multicenter trial of Korean Cancer Study Group (UN10-06)","volume":"20","author":"Lee","year":"2015","journal-title":"Oncologist"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-14-1630","article-title":"Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition","volume":"21","author":"Carvajal","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R10-20250504","first-page":"1380","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Oncology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","article-title":"Immunological off-target effects of imatinib","volume":"13","author":"Zitvogel","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/1535-7163.MCT-16-0676","article-title":"Anti-KIT monoclonal antibody treatment enhances the antitumor activity of immune checkpoint inhibitors by reversing tumor-induced immunosuppression","volume":"16","author":"Garton","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41467-020-20600-7","article-title":"Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy","volume":"12","author":"Somasundaram","year":"2021","journal-title":"Nat Commun"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1111\/jdv.15246","article-title":"Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody","volume":"33","author":"Yamashita","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e17769","DOI":"10.1097\/MD.0000000000017769","article-title":"Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: a case report","volume":"98","author":"Abdou","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and melanoma: biological insights and clinical implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:08:03Z","timestamp":1746335283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027832"}},"subtitle":["A phase I\/II trial and study protocol"],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":18,"journal-issue":{"issue":"49","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027832","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"2021-10-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}